Rasmussen's encephalitis: mechanisms update and potential therapy target.

Area of Science:

• Neuroimmunology
• Neurology
• Pediatric Neurology

Background:

• Rasmussen's encephalitis (RE) is a rare, progressive neurological disorder affecting one brain hemisphere, leading to seizures, hemiparesis, and cognitive decline.
• Pathogenesis remains uncertain, with cerebral hemispherectomy being the primary intervention for seizure control.
• Current research explores viral infections, antibody-mediated responses, cell-mediated immunity, and microglia activation as potential contributors.

Purpose of the Study:

• To review and synthesize current understanding of Rasmussen's encephalitis pathogenesis.
• To explore potential immune-mediated mechanisms, including T cell responses and microglia activation.
• To identify novel therapeutic targets for RE, such as the adenosine system.

Main Methods:

• Review of existing literature on Rasmussen's encephalitis pathogenesis.
• Analysis of immunological pathways involved in RE, including adaptive (CD8+ T cells) and innate (microglia) immunity.
• Examination of the role of the adenosine system in RE.

Main Results:

• While T cell responses are observed in RE brain tissue, a definitive causative antigen is unconfirmed.
• Antibody presence in RE appears to be a secondary phenomenon.
• Evidence suggests both CD8+ T cell-mediated adaptive immunity and activated microglia-driven innate immunity play roles in RE.

Conclusions:

• Immunomodulatory treatments targeting cytotoxic CD8+ T cells and microglia may slow RE progression.
• Further large-scale, multicenter studies are required to validate these immunomodulatory treatment theories.
• Dysfunction in the adenosine system presents a promising novel therapeutic avenue for Rasmussen's encephalitis.